Dana­her/Ab­cam deal set to close next month; Cereno's loan; March Bio­sciences to ad­vance its CAR-T in­to PhII

Dana­her’s pro­posed ac­qui­si­tion of Ab­cam is ex­pect­ed to close Dec. 6: The com­pa­nies an­nounced the clos­ing date on Fri­day. Dana­her is pay­ing $24 a share in cash. Jonathan Mil­ner, Ab­cam’s founder and largest share­hold­er, had cam­paigned against the deal un­til ear­li­er this month.

Cereno Sci­en­tif­ic’s loan: The Swedish bio­phar­ma de­vel­op­ing car­dio­vas­cu­lar treat­ments said Fri­day it re­ceived a loan for SEK 90 mil­lion, about $8.5 mil­lion. For­mue Nord Fokus is­sued the loan, which is di­vid­ed in­to two tranch­es, at a set-up fee of 5%. “We have se­cured op­ti­mal con­di­tions to be able to main­tain a strong po­si­tion in dis­cus­sions and po­ten­tial ne­go­ti­a­tions with part­ners over an ex­tend­ed pe­ri­od,” Cereno CEO Sten Sörensen said in a re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.